Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Net sales totaled $16.2 million in Q2 2025, Net sales increased 23% in the second quarter. This marks the third straight quarter of year-over-year revenue growth. OEM Net Sales-- OEM segment net sales ...

Q2 2025 Earnings Call Transcript August 13, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $-0.19, expectations ...

Reports Q2 revenue $98.61M vs. $63.14M last year. “The second quarter marked a surge in our growth momentum with net revenues soaring over 50% year-over-year and net income exceeding RMB40 million, ...

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Honda and Acura have a pattern of showing multiple stages of concepts, those that we would more traditionally think of as ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Q2 2025 Earnings Conference Call August 14, 2025 10:00 AM ETCompany ParticipantsAnthea Ingrid Bath - President, ...